Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts

Author： Balandin Taras   Edelweiss Evelina   Andronova Natalia   Treshalina Elena   Sapozhnikov Alexander   Deyev Sergey  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.29, Iss.1, 2011-02, pp. : 22-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Growth of ovarian cancer cells that overexpress p185HER-2 is inhibited by scFv(FRP5)-ETA

By  

Inpharma, Vol. 1, Iss. 1282, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer

By Laginha Kimberley   Moase Elaine   Yu Ning   Huang Anthony   Allen T. M.  

Journal of Drug Targeting, Vol. 16, Iss. 7-8, 2008-08 ,pp. : 605-610

Informa Healthcare

Access to resources Recommend Favorite

The HER2 CISH pharmDx ™ Kit in the assessment of breast cancer patients for anti-HER2 treatment

By Foged Niels T   Brügmann Anja   Jørgensen Jan T  

Expert Review of Molecular Diagnostics, Vol. 13, Iss. 3, 2013-04 ,pp. : 233-242

Informa Healthcare

Access to resources Recommend Favorite

Anti-HER2 Cancer Therapy and Cardiotoxicity

By  

Current Pharmaceutical Design, Vol. 20, Iss. 30, 2014-09 ,pp. : 4911-4919

Bentham Science Publishers

Access to resources Recommend Favorite

Control-Relevant Modeling of the Antitumor Effects of 9-Nitrocamptothecin in SCID Mice Bearing HT29 Human Colon Xenografts

By Harrold John   Eiseman Julie   Joseph Erin   Strychor Sandra   Zamboni William   Parker Robert  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 32, Iss. 1, 2005-02 ,pp. : 65-83

Springer Publishing Company

Access to resources Recommend Favorite